Baseline characteristics
| Characteristics | eGFR ≥90 (n=618) | eGFR 60–89 (n=3775) | eGFR 30–59 (n=1965) | eGFR 15–29 (n=175) | eGFR <15/dialysis (n=34) |
| Demographics | |||||
| Age, years, median (IQR) | 63.6 (57.4–68.7) | 75.7 (69.7–82.2) | 83 (76.9–88.2) | 85.8 (78.8–91.0) | 79.2 (75.3–84.3) |
| Sex, female, n (%) | 461 (74.6) | 2264 (60.0) | 957 (48.7) | 84 (48.0) | 23 (67.6) |
| Medical history, n (%) | |||||
| Hypertension | 294 (47.6) | 1985 (52.6) | 1371 (69.8) | 132 (75.4) | 31 (91.2) |
| Diabetes mellitus | 104 (16.8) | 549 (14.5) | 390 (19.8) | 58 (33.1) | 12 (35.3) |
| Prior stroke | 45 (7.3) | 316 (8.4) | 260 (13.2) | 25 (14.3) | 5 (14.7) |
| Prior TIA | 15 (2.4) | 176 (4.7) | 103 (5.2) | 14 (8.0) | 3 (8.8) |
| Prior systemic embolism | 2 (0.3) | 22 (0.6) | 29 (1.5) | 7 (4.0) | 1 (2.9) |
| Prior MI | 34 (5.5) | 290 (7.7) | 214 (10.9) | 35 (20.0) | 5 (14.7) |
| Prior PCI or CABG | 46 (7.4) | 385 (10.2) | 283 (14.4) | 43 (24.6) | 6 (17.6) |
| Heart failure | 39 (6.3) | 294 (7.8) | 368 (18.7) | 68 (38.9) | 9 (26.5) |
| Peripheral vascular disease | 17 (2.8) | 155 (4.1) | 112 (5.7) | 22 (12.6) | 5 (14.7) |
| COPD | 38 (6.1) | 226 (6.0) | 143 (7.3) | 19 (10.9) | 2 (5.9) |
| Cancer (within 3 years) | 29 (4.7) | 188 (5.0) | 132 (6.7) | 12 (6.9) | 4 (11.8) |
| Prior major bleeding | 35 (5.7) | 215 (5.7) | 186 (9.5) | 29 (16.6) | 6 (17.6) |
| CHA2DS2-VASc, median (IQR) | 1 (0–2) | 2 (1–4) | 4 (2–4) | 4 (3–5) | 4 (3–5) |
| Biochemical analyses, median (IQR) | |||||
| Number of eGFR measures | 4 (2–6) | 4 (2–7) | 5 (2–9) | 5 (2–10) | 5 (2–8) |
| eGFR (mL/min/1.73 m2) | 94.6 (92.2–98.5) | 75.3 (68.0–82.1) | 49.4 (42.1–55.5) | 25.7 (22.4–28.2) | 12.0 (10.2–12.9) |
| Number of INR measures (n=3602) | 44 (19–73) | 50 (24–78) | 49 (21–79) | 31 (13–62) | 43 (12–86) |
| INR (g/L) | 2.4 (2.1–2.8) | 2.4 (2.1–2.8) | 2.4 (2.1–2.8) | 2.0 (2.1–2.8) | 2.0 (2.1–2.9) |
| TTR (%) (n=3514) | 73.7 (62.5–83.5) | 78.6 (68.4–85.8) | 76.3 (66.7–84.2) | 70.0 (54.1–79.1) | 67.3 (53.8–77.0) |
| TTR >70%, n (%) | 183 (58.1) | 1441 (72.4) | 729 (68.5) | 58 (49.6) | 12 (42.9) |
| TTR >60%–70%, n (%) | 65 (20.6) | 281 (14.1) | 165 (15.5) | 23 (19.7) | 5 (17.9) |
| TTR <60%, n (%) | 67 (21.3) | 267 (13.4) | 171 (16.1) | 36 (30.8) | 11 (39.3) |
| Medication, n (%) | |||||
| Warfarin | 331 (53.6) | 2064 (54.7) | 1113 (56.6) | 126 (72.0) | 32 (94.1) |
| DOAC | 287 (46.4) | 1708 (45.2) | 851 (43.3) | 49 (28.0) | 2 (5.9) |
| Dabigatran etexilate | 67 (10.8) | 292 (7.7) | 102 (5.2) | 0 (0.0) | 0 (0.0) |
| Rivaroxaban | 27 (4.4) | 202 (5.4) | 103 (5.2) | 1 (0.6) | 1 (2.9) |
| Apixaban | 193 (31.2) | 1211 (32.1) | 646 (32.9) | 48 (27.4) | 1 (2.9) |
| Edoxaban | 0 (0.0) | 3 (0.1) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Other OACs | 0 (0.0) | 3 (0.1) | 1 (0.1) | 0 (0.0) | 0 (0.0) |
| Acetylsalicylic acid | 121 (19.6) | 985 (26.1) | 632 (32.2) | 77 (44.0) | 16 (47.1) |
| P2Y12 inhibitor | 14 (2.3) | 132 (3.5) | 75 (3.8) | 11 (6.3) | 2 (5.9) |
Values are median (IQR) for continuous variables and n (%) for categorical variables.
eGFR levels are based on the Chronic Kidney Disease Epidemiology Collaboration equation.
CABG, coronary artery bypass grafting; CHA2DS2-VASc, congestive heart failure, hypertension, age, diabetes mellitus, stroke/transient ischemic attack/thromboembolism history, vascular disease history and sex; COPD, chronic obstructive pulmonary disease; DOAC, direct oral anticoagulant; eGFR, estimated glomerular filtration rate; INR, international normalised ratio; MI, myocardial infarction; OAC, oral anticoagulant; PCI, percutaneous coronary intervention; TIA, transient ischaemic attack; TTR, time in therapeutic range.